
Valerio Rosato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4111798/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Factors affecting longâ€term changes of liver stiffness in directâ€acting antiâ€hepatitis C virus therapy: A multicentre prospective study. Journal of Viral Hepatitis, 2022, 29, 26-34.	1.0	10
2	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 2022, 11, 609.	1.3	7
3	Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology, 2022, 11, 805.	1.3	2
4	Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. Biology, 2022, 11, 800.	1.3	2
5	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses, 2022, 14, 1096.	1.5	9
6	Factors Enhancing Treatment of Hepatitis C Virus–Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. American Journal of Gastroenterology, 2021, 116, 1248-1255.	0.2	5
7	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients, 2021, 13, 1314.	1.7	34
8	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life, 2021, 11, 17.	1.1	6
9	Unusual liverâ€related heart injury. JCH Open, 2020, 4, 1240-1241.	0.7	Ο
10	The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine, 2020, 1, .	1.5	6
11	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. International Journal of Environmental Research and Public Health, 2019, 16, 3415.	1.2	90
12	Realâ€life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver International, 2019, 39, 1852-1859.	1.9	31
13	Preclinical evaluation of Endothelial Dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles in NAFLD. Digestive and Liver Disease, 2019, 51, e27-e28.	0.4	1
14	FRI-326-Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles. Journal of Hepatology, 2019, 70, e539.	1.8	0
15	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. Antiviral Therapy, 2018, 23, 129-138.	0.6	33
16	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection, 2018, 46, 231-238.	2.3	13
17	Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study. Respiratory Physiology and Neurobiology, 2018, 255, 7-10.	0.7	11
18	Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate—a pilot study. Internal and Emergency Medicine, 2018, 13, 901-906.	1.0	3

VALERIO ROSATO

#	Article	IF	CITATIONS
19	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-12.	1.9	28
20	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-14.	1.9	447
21	"Non alcoholic fatty liver disease and eNOS dysfunction in humans― BMC Gastroenterology, 2017, 17, 35.	0.8	45
22	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World Journal of Gastroenterology, 2017, 23, 1458.	1.4	38
23	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS ONE, 2017, 12, e0178473.	1.1	79
24	Pharmacotherapy of alcoholic liver disease in clinical practice. International Journal of Clinical Practice, 2016, 70, 119-131.	0.8	24
25	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. Reviews on Recent Clinical Trials, 2016, 11, 159-166.	0.4	30
26	Epidemiology and Natural History of Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 167-174.	0.4	52
27	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy―Experience in Southern Italy. Reviews on Recent Clinical Trials, 2016, 11, 306-316.	0.4	4
28	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. Annals of Hepatology, 2015, 14, 325-332.	0.6	3
29	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. Hepatitis Monthly, 2015, 15, e18640.	0.1	7
30	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. Annals of Hepatology, 2015, 14, 325-32.	0.6	0
31	The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. BMC Research Notes, 2014, 7, 59.	0.6	6
32	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterology, 2014, 14, 31.	0.8	24